Loading…
← CockpitCompetitor Analysis › 1681.HK Consun Pharmaceutical Group Ltd.Open in the cockpit ↗

Consun Pharmaceutical Group Ltd.1681.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major

Chinese pharmaceutical company making traditional-Chinese-medicine-derived drugs, notably for kidney disease.

≈ A niche Chinese TCM-derived nephrology drug makerMomentum leader 90
Mkt cap
$1.65B
US dollars, full cap
Free float
54%
of shares outstanding
$/day
$2.41M
20-day average traded
Fwd P/E
9.2×
forward earnings
ROIC−WACC
+59.7 pp
WACC 7.5%
Hurdle
-28 pp
Req g minus delivered
Next earnings
126 days
24 Mar 2027
Close · HKDHK$15.87
1D+1.0%
1W-0.9%
1M-1.1%
3M+19.3%
6M+7.5%
YTD+1.5%
1Y+5.6%
ATR %2.5%
52w lowhigh18.6% off high

What Consun Pharmaceutical does

Chinese pharmaceutical company making traditional-Chinese-medicine-derived drugs, notably for kidney disease.

In one line: A niche Chinese TCM-derived nephrology drug maker.

Products and services

  • Kidney-disease TCM drugs
  • Other TCM formulations

Customers

  • Hospitals and pharmacies in China

Where it sits in the supply chain

  • Pharmaceuticals
  • TCM-derived drugs
  • Nephrology/kidney-disease drugs

What could go right

  • Chronic kidney disease treatment demand in China

What could go wrong

  • Centralized procurement pricing pressure

Moat: narrow (brand, IP / patents). Branded, patent-protected TCM formulations in a niche nephrology segment.

Headquarters: Guangzhou, China · Founded: 1998 · Employees: 3,115

Named competitors

Consun Pharmaceutical at a glance

Size Consun Pharmaceutical (1681.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $1.65B, the 455th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$15.87 on 18 Nov 2026.

Performance Over six months the shares gained 7.5%, against -11.9% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 4th highest of 20 in its peer set.

Growth Revenue grew 15.1% over the last twelve months (peer median +6.6%); the operating margin is 35.5% (peer median 12.0%).

Valuation It trades at 9.2× forward earnings against a peer median of 26.3× (cheapest of 16).

Price implies For today's price to make sense, revenue must grow about -15% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -28 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 59.7 points above its cost of capital (7.5% WACC).

Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 20261681.HK 110Peer median 90
Six months, rebased to 100: Consun Pharmaceutical against the median of its 20 peers (local-currency closes).

Consun Pharmaceutical financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$4.06BHK$3.71BHK$3.22BHK$2.86BHK$2.72B
Revenue growth—+15%+12%+5%—
Gross profitHK$3.25BHK$2.89BHK$2.43BHK$2.12BHK$2.05B
EBITDAHK$1.52BHK$1.32BHK$1.11BHK$933MHK$903M
Net incomeHK$1.31BHK$1.17BHK$987MHK$867MHK$794M
Free cash flowHK$1.73BHK$1.34BHK$1.10BHK$898MHK$1.08B
Capital expenditureHK$81.1MHK$74.3MHK$118MHK$58.1MHK$60.0M
Total debtn/aHK$299MHK$284MHK$563MHK$517M

Quarterly statements and history in the cockpit →

Consun Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%+20%-20%0%+20%300357000766ASTRAZENINDGN600993ANURASCAPLIPOINT300723301047FAEMAZE002755600420688166JUBLPHARMA002675NATCOPHARM002019SRPT1681.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Consun Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%20×40×60×80×300357INDGN600993ANURASCAPLIPOINT300723301047FAE002755600420688166JUBLPHARMA002675NATCOPHARM0020191681.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Consun Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%300357000766ASTRAZENINDGN600993CAPLIPOINT300723301047FAE002755600420688166002675NATCOPHARMSRPT1681.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Consun Pharmaceutical is the large dot.

Consun Pharmaceutical competitors and peer comparison

Head to head with its named competitors (1681.HK vs 3320.HK vs 0874.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Consun Pharmaceutical 1681.HK$1.65B+8%+15%35%9.2×-14.9%
China Resources Pharmaceutical 3320.HK$3.60B-7%+8%4%5.8×-4.9%
Guangzhou Baiyunshan Pharmaceutical 0874.HK$4.48B-23%+6%3%7.0×1.3%

How Consun Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Consun Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure1681.HKPeer medianRank in peer set
1-month return-1.1%-3.9%9th highest of 21
6-month return+7.5%-11.9%4th highest of 20
Distance from 52-week high-18.6%-36.7%5th highest of 21
Revenue growth (TTM)+15.1%+6.6%8th highest of 20
Operating margin35.5%12.0%2nd highest of 20
Forward P/E9.2×26.3×cheapest of 16
Growth the price implies (Req g, 7 yrs)-14.9%18.4%least demanding of 16
Growth delivered (Del g)+13.5%+9.2%6th highest of 16
Hurdle (Req g minus delivered)-28.4 pp+8.6 pp2nd least demanding of 16
ROIC minus cost of capital+59.7 pp-2.4 pphighest of 21
EV / EBITDA5.9×21.4×cheapest of 8
Net debt / EBITDA-2.9×0.6×least indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Consun Pharmaceutical 1681.HKHong Kong$1.65B+8%+15%35%9.2×-14.9%+13.5%
Braveheart Bio BRVEUnited States$1.67Bn/an/an/an/an/an/a
Zhejiang Wolwo Bio-Pharmaceutical 300357.SZChina$1.67B-12%+7%39%26.3×18.4%+10.8%
Tonghua Golden-Horse Pharmaceutical Industry 000766.SZChina$1.62B-47%-18%9%n/a33.0%+0.9%
AstraZeneca Pharma India ASTRAZEN.NSIndia$1.62B-30%+30%10%n/a42.4%+23.0%
Indegene INDGN.NSIndia$1.69B+28%+36%12%29.5×31.4%+29.4%
Mayinglong Pharmaceutical 600993.SSChina$1.70B+2%+7%17%17.0×-3.5%+6.8%
Anupam Rasayan India ANURAS.NSIndia$1.61B-3%+24%16%49.9×n/an/a
Caplin Point Laboratories CAPLIPOINT.NSIndia$1.70B+2%+17%31%21.4×24.3%+15.7%
ApicHope Pharmaceutical 300723.SZChina$1.70B-36%-28%-50%22.0×11.3%-11.0%
Sino Biological 301047.SZChina$1.60B+27%+20%17%51.6×31.1%-15.1%
Faes Farma FAE.MCSpain$1.71B+6%+32%14%17.4×3.7%+9.9%
Maze Therapeutics MAZEUnited States$1.71B+27%-100%-821%n/an/an/a
Beijing Aosaikang Pharmaceutical 002755.SZChina$1.60B-31%-13%12%57.4×12.8%-14.0%
Shanghai Shyndec Pharmaceutical 600420.SSChina$1.59B-14%-13%6%12.6×-6.6%-5.6%
BrightGene Bio-Medical Technology 688166.SSChina$1.71B-57%+14%7%74.9×35.3%+9.2%
Jubilant Pharmova JUBLPHARMA.NSIndia$1.59B-8%+18%7%29.0×n/an/a
Yantai Dongcheng Biochemicals 002675.SZChina$1.59B0%-4%15%47.2×6.0%-4.3%
NATCO Pharma NATCOPHARM.NSIndia$1.73B-27%-30%17%19.1×20.5%+19.0%
Yifan Pharmaceutical 002019.SZChina$1.57B-19%-5%8%25.6×n/an/a
Sarepta Therapeutics SRPTUnited States$1.56B-15%-19%0%n/a-6.8%+32.4%

Questions

Who are Consun Pharmaceutical's main competitors?
Named competitors: China Resources Pharmaceutical (3320.HK), Guangzhou Baiyunshan (0874.HK). The cockpit's measured peer set (industry) also includes Braveheart Bio (BRVE), Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ), Tonghua Golden-Horse Pharmaceutical Industry (000766.SZ), AstraZeneca Pharma India (ASTRAZEN.NS), Indegene (INDGN.NS), Mayinglong Pharmaceutical (600993.SS).
Is Consun Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 9.2× against a peer median of 26.3×, cheapest of 16 in its peer set. For today's price to make sense, revenue must grow about -15% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -28 pp: the price already allows for a slowdown.
How has Consun Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned +7.5% against -11.9% for the median peer; over one year +5.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.